Infectomycin

Quick links to important sections

Infectomycin

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Infectomycin

Property Description
Active ingredient Azithromycin
Form Tablets, Capsules, Suspension, Injection
Pharmacological class Macrolide Antibiotic (Azalide subclass)
Common use Managing bacterial infections
Origin Synthetic (Semisynthetic derivative)

Defining a Systemic Antibacterial Agent

Infectomycin is a widely utilized prescription-only medicine (POM) that functions as a systemic antibacterial agent, meaning its primary role is managing and helping the body clear infections caused by specific susceptible bacteria. The core of this medication is its active ingredient, Azithromycin, a synthetic compound that is a derivative of the macrolide class. This substance is designed to be administered throughout the body, making it a powerful internal defense against microbial threats.

Azithromycin is classified as a macrolide antibiotic with a bacteriostatic effect, meaning it stops bacteria from multiplying. This property effectively reduces microbial spread. The primary general purpose of Infectomycin is, therefore, to halt the progression of an infection to facilitate the body's natural recovery process.

Classification and Mechanism of Action

Azithromycin is classified as an azalide, a specialized subclass of the macrolide antibiotic family. This classification is functionally significant because the Azalide structure provides the drug with enhanced pharmacokinetic properties, including a longer duration of action and high concentrations in infected tissues.

Azithromycin acts by inhibiting protein synthesis in susceptible organisms, effectively stopping their essential life functions. This mechanism prevents the bacteria from replicating and forming colonies. Infectomycin is provided in various pharmaceutical preparations, including film-coated tablets for oral administration and powder for solution for injection for parenteral administration, ensuring appropriate delivery across various patient needs.

Regulatory References

  1. Azithromycin: MedlinePlus Drug Information
  2. Macrolides - StatPearls - NCBI Bookshelf

What side effects are possible with Infectomycin?

Infectomycin: Possible side effects and safety information

Infectomycin (a systemic fluoroquinolone antibiotic) carries an official Boxed Warning from regulatory authorities regarding the risk of serious, disabling, and potentially permanent adverse reactions that can occur together in the same patient. Consequently, regulatory guidance advises reserving its use for certain uncomplicated infections when no other treatment options are available.


Serious and Clinically Significant Adverse Reactions

The following are documented as serious or clinically significant risks, sometimes occurring within hours to weeks of starting treatment:

System-Organ Class Serious Adverse Reactions (Boxed Warning & Warnings Section)
Musculoskeletal & Peripheral Nervous Tendinitis and Tendon Rupture (most common in the Achilles tendon), muscle pain, muscle weakness, joint pain/swelling, and Peripheral Neuropathy (numbness, tingling, or burning sensation in the limbs).
Central Nervous System (CNS) Psychosis, suicidal thoughts/behavior, hallucinations, confusion, anxiety, depression, insomnia, and memory impairment.
Other Worsening of Myasthenia Gravis, QT prolongation (which can lead to an abnormal, rapid heart rhythm), severe allergic/hypersensitivity reactions (including anaphylaxis), and Clostridium difficile-associated diarrhea (CDAD).

Risk factors for tendon injury include older age (over 60), use of corticosteroids, and a history of kidney, heart, or lung transplants. These severe effects may persist for months or become permanent.


Common Side Effects

Adverse reactions reported with common frequency include nausea, diarrhea, headache, dizziness, lightheadedness, and trouble sleeping.


Monitoring and Safety Notes

Official prescribing information emphasizes that Infectomycin should be immediately discontinued at the first sign of a serious adverse reaction (such as tendon pain, muscle weakness, or a change in mood or sensation) to avoid further exposure. Patients at risk for heart rhythm problems or with pre-existing myasthenia gravis require particular caution and monitoring.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the official overdose information documented in government regulatory sources and the actions mandated when an overdose is suspected.

Overdose scope Official Regulatory Statement
Documented Manifestations Adverse reactions experienced in higher than recommended doses are similar to those seen at normal doses, primarily including pronounced gastrointestinal disturbances such as nausea, vomiting, diarrhoea, and stomach discomfort [2.4].
Life-Threatening Risk The most serious, officially documented outcome is the potential for Prolongation of the QT interval, which imparts a risk of developing serious ventricular arrhythmias, including Torsades de pointes [2.7].
Population-Specific Note The risk of developing these severe cardiac arrhythmias is a heightened concern in elderly patients and those with existing cardiovascular risk factors [2.6].
Required Emergency Action If an overdose is suspected, immediate medical attention must be sought [1.2]. Immediate contact with emergency services is mandated if the affected individual has collapsed, is having trouble breathing, or cannot be awakened [1.2].
Supportive Management The official management strategy involves general symptomatic and supportive measures [2.4]. The administration of medicinal charcoal (activated charcoal) is specifically indicated as a supportive measure [3.2].

The official overdose profile is structured to emphasize that although common manifestations are related to the digestive system, the critical concern is the rare but potentially fatal cardiac complication officially associated with the drug's use [2.1]. This severe risk of a heart rhythm abnormality directly dictates the regulatory requirement that emergency medical care must be sought immediately following a suspected overdose [1.2]. Management, as documented in prescribing information, is entirely supportive, treating the resulting symptoms due to the lack of a specific antidote [3.2].

Therapeutic Uses of Infectomycin

What Infectomycin Treats: Main Uses and Benefits

Infectomycin (Azithromycin) is a systemic antibacterial agent commonly used for managing infections caused by specific susceptible bacteria. Its primary therapeutic benefit is addressing the underlying bacterial cause, which supports the body in managing the acute symptomatic phase. This medication is applied across conditions presenting with systemic or localized discomfort, including infections of the respiratory tract, skin, and reproductive organs.

This medication is generally applied in clinical settings that involve acute or unstable symptom patterns, including the treatment of acute respiratory infections (such as infections associated with susceptible bacteria causing inflammation of the throat or bronchial tubes), skin and soft tissue infections (such as cellulitis or impetigo), and sexually transmitted infections (such as infections associated with susceptible pathogens causing urethritis or pharyngitis). It helps address symptom clusters like fever, painful cough, sore throat, and localized swelling—symptoms that interfere with daily functioning.

“It provides supportive relief that helps patients cope more steadily with difficult acute episodes.”

Applied across these domains, Infectomycin contributes to improved comfort during periods of heightened symptoms and provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Acute Symptomatic Burden

  • Context: Commonly used when short-term symptomatic assistance is needed in conditions characterized by periods of heightened symptoms.
  • Benefit: Provides support that helps ease the overall symptom burden and supports patients during episodes of heightened discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Infectomycin (a macrolide antibiotic) is prescribed to treat various bacterial infections, including respiratory, skin, and ear infections, as well as certain sexually transmitted infections. It may also be used for patients with penicillin allergies.

However, this medication is not suitable for everyone, and its use must be carefully evaluated by a healthcare professional, especially due to potential interactions and side effects.


Contraindications

Condition Risk/Reason for Caution
Allergy to Infectomycin or other macrolide antibiotics Risk of severe allergic reaction.
Prolonged QT interval (a heart rhythm disorder) or Bradycardia (slow heart rate) Increased risk of serious, potentially fatal, heart rhythm changes.
Use with certain medications Specifically, drugs like cisapride, pimozide, ergotamine, and some statins (e.g., lovastatin, simvastatin) should be avoided due to dangerous drug interactions.
Severe liver impairment Increased drug toxicity and potential for worsening liver damage.

Special Populations and Considerations

Population Caution/Monitoring Required
Infants (especially under two weeks old) Associated with an increased risk of Infantile Hypertrophic Pyloric Stenosis (IHPS).
Pregnancy and Breastfeeding Generally considered safe, but use requires professional consultation. Monitor breastfeeding infants for diarrhea or vomiting.
Elderly Patients May be more susceptible to hearing loss and heart rhythm issues; dosage may require adjustment.
Myasthenia Gravis May worsen symptoms of severe muscle weakness.

What should I know about interactions with other medicines?

The official regulatory documentation for Infectomycin (Azithromycin) describes documented interactions focusing on changes in drug exposure and risk of pharmacodynamic effects.

Interaction Classifications (High-Level)

Classification Interacting Agents Official Regulatory Statement
Contraindicated Ergot Alkaloids (e.g., Ergotamine) Use is contraindicated due to the theoretical potential for acute ergotism, a risk noted with other macrolides.
High Caution/Risk Drugs that Prolong the QT Interval (e.g., Pimozide) Co-administration increases the potential risk of cardiac arrhythmia due to an additive pharmacodynamic effect on cardiac repolarization.
Requires Monitoring Warfarin (Oral Anticoagulant) Post-marketing reports suggest potential to potentiate the effects of oral anticoagulants, requiring careful monitoring of prothrombin time.

Exposure-Modifying and Procedural Constraints

Co-administration with the antiretroviral Nelfinavir is documented to result in a significant pharmacokinetic increase in Azithromycin plasma concentrations (AUC and C max). The official profile also includes a mandatory timing rule for substances that affect absorption: aluminum- or magnesium-containing Antacids must be administered with a two-hour separation from Azithromycin to prevent a reduction in its peak plasma concentration ( C max). Systemic exposure is also officially noted to be significantly increased in patients with severe renal impairment.

Mechanism of Action

Targeting the Bacterial Protein Factory

Infectomycin (Azithromycin) functions as an inhibitor by engaging a core biological target within susceptible bacteria: the 50S ribosomal subunit. By binding to the 23S ribosomal RNA, the drug rapidly arrests the synthesis of essential bacterial proteins by inhibiting the translocation step necessary for the ribosome to move along the mRNA. This molecular blockade results in a bacteriostatic effect, halting the propagation of microbial populations and resulting in a reduction of the viable microbial load.

️ Modulating Host Inflammation and Intracellular Delivery

Beyond ribosomal inhibition, the drug's mechanism involves its ability to be actively concentrated within host phagocytic cells (e.g., macrophages), which results in the accumulation of the drug at high concentrations within the site of microbial presence. Concurrently, Infectomycin acts as a modulator of specific host immune pathways, influencing the production of pro-inflammatory mediators such as IL-8. This dual mechanism results in the modulation of the tissue inflammatory response, thereby assisting the physiological process of microbial clearance.

Constraints of the Binding Mechanism

The mechanism is physiologically constrained by acquired bacterial resistance, specifically when the microbe produces enzymes that modify the drug's ribosomal binding site or when the microbe develops active efflux pumps to expel the drug. In these cases, the drug is functionally prevented from interacting with its 50S target, rendering the desired bacteriostatic effect ineffective.

Dosage and Administration Information

Instruction Map: How to use Infectomycin — Administration Guidelines

Category Instructions
Route of administration Oral (tablets, suspension) and Intravenous (IV) Infusion. The IV formulation must not be administered as a bolus or intramuscular injection.
Dosing schedule Standard short-course adult regimens include 500 mg on Day 1, followed by 250 mg on Days 2 through 5, or 500 mg once daily for 3 days. Single 1 g or 2 g doses are also used.
Timing in relation to meals Tablets and oral suspension can be taken with or without food. However, certain capsule forms must be taken at least one hour before or two hours after a meal to ensure proper absorption.
Preparation requirements The powder for oral suspension requires reconstitution. The 500 mg IV powder must be reconstituted and further diluted to a concentration of 1 mg/mL or 2 mg/mL before infusion.
Age-group administration rules Pediatric dosing is calculated based on body weight (mg/kg). No dose adjustment is generally specified for most older adults or for patients with mild to moderate renal impairment.
Missed-dose rules If a dose is missed, it should be taken as soon as it is remembered. If it is almost time for the next dose, the missed dose should be skipped to prevent doubling.
Special procedural conditions The diluted IV solution must be administered slowly by infusion over a period of 60 minutes or longer. Treatment is administered at a once-daily frequency and is typically limited to a fixed, short-term duration of 3 to 10 days.

Connection to the overall use protocol: The instructions establish a structured, fixed-course administration protocol, mandating once-daily frequency via either the oral or slow intravenous route. This protocol dictates the required total dosage over a defined, short-term duration and specifies precise administration conditions, such as meal timing and IV dilution protocols, to ensure standardized use.

Recent Clinical Evidence

Research evidence / Overview of studies for Infectomycin

Evidence for Acute Bacterial Respiratory Tract Infections

Research on Infectomycin for bacterial respiratory tract infections (RTIs) has been conducted primarily using Randomized Controlled Trials (RCTs). These studies explored the drug’s performance in research settings involving adult and pediatric patients. The research compared Infectomycin against other common treatment regimens to observe patterns related to changes in the infection’s status. Studies monitored outcomes designed to measure changes in clinical status and pathogen presence. Findings describe patterns observed in the studies related to short-term symptomatic changes and clinical status measurements at the end of the treatment period. Long-term effects are not fully established, and resistance surveillance is continuous.

Evidence for Acute Skin and Soft Tissue Infections

The research base for skin and soft tissue infections (SSTIs) also includes comparative clinical trials and RCTs. Research examined the drug’s performance in research settings involving adults and children with uncomplicated infections like cellulitis. Researchers measured outcomes designed to determine clinical success rates and microbiological response. Follow-up durations were limited, meaning there is limited information for long-term outcomes such as rates of recurrence, and evidence quality varies across historical studies.

Evidence for Acute Sexually Transmitted Infections

Infectomycin was evaluated in studies for its use against specific sexually transmitted infections (STIs) caused by susceptible bacterial organisms. Research includes studies evaluating short-course regimens which were studied against multi-day treatments. The key outcomes evaluated were measurements of microbiological status and clinical outcome status. Data remain limited for infections located at extragenital sites, and research is ongoing to monitor and address antimicrobial resistance (AMR). The foundational evidence used in regulatory evaluations relies mainly on limited follow-up durations.

Frequently Asked Questions (FAQ)

Common questions about Infectomycin (FAQ)


Q: Why do some people say Infectomycin is stronger than other similar medicines?

Official product information describes Infectomycin as belonging to a specialized group of antibiotics (azalides). This structure provides enhanced properties, allowing the medication to achieve higher concentrations and have a longer duration of action in infected body tissues. These pharmacological differences may be the reason why the medication is sometimes described in terms of having greater effect compared to other antibiotics.


Q: Is Infectomycin safe for older adults (the elderly)?

According to official regulatory documents, a dose adjustment is generally not specified for most older adults. However, advanced age (over 60) is noted as a risk factor for serious side effects, such as tendon injury. Elderly patients may also be more susceptible to certain heart rhythm issues, and these specific risks are why the official documentation highlights the need for particular caution and monitoring.


Q: Can Infectomycin affect the use of birth control pills?

Official regulatory information indicates that this antibiotic generally does not reduce the effectiveness of hormonal birth control pills. However, if the medication causes severe and prolonged side effects like vomiting or diarrhea, the absorption and effectiveness of oral contraceptives may be reduced. Patients who rely on oral contraceptives should review potential risks with a physician.


Q: What is the evidence regarding Infectomycin's use in children?

Official guidelines confirm that dosing for children is calculated based on body weight. Studies have been conducted on its use for respiratory and skin infections in pediatric patients. However, there is a specific regulatory warning associated with using the drug in infants under two weeks old due to a rare risk called Infantile Hypertrophic Pyloric Stenosis (IHPS).


Q: Are there any documented interactions between Infectomycin and alcohol?

Official product information does not typically document a dangerous chemical interaction between this medication and alcohol. Nevertheless, combining the two may worsen common side effects like nausea, dizziness, or headache. Consuming alcohol while being treated for an infection can also hinder the body’s recovery process.


Q: Can Infectomycin interact with common supplements like vitamins or herbal remedies?

Regulatory documents list specific interactions with other prescription medications but may not include general vitamins or herbal remedies individually. Due to potential risks, regulatory guidance emphasizes the importance of disclosing all products being taken, including vitamins and herbal remedies, to a physician.


Q: How does the way Infectomycin works differ from older generations of medicine?

Infectomycin is classified as an Azalide, which represents a structural advancement over older Macrolide antibiotics. This structural difference results in enhanced drug properties, such as its ability to achieve high concentrations in tissues and maintain a long duration of action within the body.


Q: Is Infectomycin ever used for infections in the urinary tract?

Regulatory documents indicate that Infectomycin is approved for managing certain infections of the lower urinary tract. This includes conditions like urethritis and cervicitis, but only when they are caused by specific types of susceptible sexually transmitted bacteria, as described in official labeling.


Q: What should be done if an allergic reaction to Infectomycin is suspected?

Official guidance requires that if an allergic reaction is suspected, the medication be immediately discontinued. Rapid medical attention and appropriate therapy are required in such cases. Professionals are warned that allergic symptoms may potentially reappear even after initial symptomatic treatment has ended.


Q: What is the shelf life of Infectomycin?

Official storage and stability information indicates that the unmixed dry product, such as tablets or powder, typically remains effective for up to 2 years from manufacture when stored correctly. However, the liquid suspension created for oral use has a much shorter stability limit and is typically discarded after 10 days from when it is first mixed.


Q: How long does Infectomycin take to start working?

Pharmacokinetic data indicates that the drug reaches its peak concentration in the bloodstream within a few hours of administration. While the full effect takes time, official supporting texts indicate that patients may begin to notice clinical improvement in their symptoms often within the first 48 hours of starting treatment.


Q: Is Infectomycin considered a 'broad-spectrum' medicine?

Yes, Infectomycin is classified by medical authorities as a broad-spectrum macrolide antibiotic. This classification is given because the medication is effective against a wide variety of susceptible bacteria, including certain Gram-positive, Gram-negative, and atypical organisms, as noted in official drug classifications.


Q: How quickly do most people start to notice improvement after starting Infectomycin?

Although individual response can vary, official information suggests that most patients may begin to notice a subjective improvement in their symptoms often within the first 48 hours after starting the course of treatment. This timeline is supported by the drug’s pharmacological profile.


Q: What is the relationship between Infectomycin and gut bacteria?

Like all antibiotics, Infectomycin can disrupt the natural balance of bacteria in the digestive system. Regulatory labels list a risk of Clostridioides difficile-associated diarrhea (CDAD), which is a serious condition resulting from this imbalance. The full scope of the drug's interaction with the patient’s non-pathogenic gut microbiome is an area of ongoing research.


Q: What is the evidence for Infectomycin treating complicated infections?

Official prescribing information advises caution regarding the use of the oral form of Infectomycin for complicated or severe infections. The drug is generally considered unsuitable in situations where a high concentration of the antibiotic is needed rapidly in the bloodstream to manage the condition, which is often the case with complicated infections.


Q: Is Infectomycin considered an important or last-resort medicine?

Infectomycin is classified as an important systemic antibacterial agent used to manage infections. However, due to certain safety considerations (like the Boxed Warning), regulatory guidance for some uncomplicated infections advises reserving its use for cases where no other appropriate treatment alternatives are available.


Q: How is Infectomycin eliminated from the body?

According to official pharmacokinetic information, the drug is primarily eliminated from the body unchanged via the faecal route. This elimination occurs through a process of biliary excretion. Only a very small percentage of the administered dose is excreted through the urine.


Q: Is Infectomycin ever used in hospitals for severe infections?

The availability of an Intravenous (IV) Infusion formulation suggests that Infectomycin is used in hospital settings for systemic delivery. However, official information advises that the oral form of the medication is not indicated for infections that require a rapid, high concentration in the blood, which may be associated with more severe cases.

How should Infectomycin be stored and disposed of?

Official Storage and Disposal Requirements

The storage and disposal of Infectomycin (Azithromycin) must strictly follow official regulatory instructions to maintain product integrity.

Storage Conditions: Solid forms (tablets and dry powder) must be stored at Controlled Room Temperature (15 C to 30 C) and protected from light and moisture. Liquid forms, such as the oral suspension, must not be frozen.

Stability Limits: The standard oral suspension must be discarded after 10 days of mixing, and the diluted intravenous solution is stable for up to 7 days under refrigeration.

Handling and Safety: The medicine must be kept in a tightly closed container and stored out of the reach of children. Unused or expired medicine, including any remaining liquid suspension, must be safely thrown away according to local guidance; it should not be disposed of in household wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Infectomycin found in:

A-Z Index: